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L AZAROIDS, 21-aminosteroids lacking steroid activity have cytoprotective properties against iron-dependent 
lipid peroxidation. 1 In addition to their antioxidant proper-
ties, lazaroids exert their cytoprotective effect hy inhibiting 
arachidonic acid release, membrane stabilization, suppres-
sion of Kuppfer cell activation. and down-regulation of 
cytokine expression and release. I- 3 While previous reports 
have shown that lazaroids are effective in reducing ischemia 
and reperfusion injury to many different organ systems, 
there have been conflicting reports of the potency of the 
various lazaroid compoundsK~ In this study. we examined 
the potency and effectiveness of the three major lazaroid 
compounds in protecting organs against ischemia and 
reperfusion injury. 
MATERIALS AND METHODS 
Two-hour complete hepatic ischemia was induced in adult female 
beagle dogs weighing 8 to 12 kg by clamping the vena cava (above 
and below the liver), the portal vein, and the hepatic artery. 
Splanchnic and inferior systemic venous beds were decompressed 
using veno-venous bypass. Total hepatic venous exclusion was 
maintained for 2 hours. Animals were divided into five groups: 
Control (n = 10. no treatment), Group F (Iazaroid, U74006F, n = 
6. 10 mglkg), Group G (Iazaroid U74389G, n = 6, 10 mglkg), 
Group Al (Iazaroid U74500A, n = 6, 10 mglkg), and Group A2 
(Iazaroid U74500A, n = 6, 5 mglkg). The lazaroids were given as a 
continuous infusion over 30 minutes, just before onset of ischemia. 
Two-week animal survival, aspartate aminotransferase (AST), ala-
nine aminotransferase (ALT), hepatic venous immunoreactive 
endothelin-l (irET-l), and plasma malondialdehyde (MDA) were 
determined serially. Intraoperative hepatic tissue blood flow 
(HTBF) was measured using a laser-doppler flow meter (ALF21; 
Advance, Co, Ltd, Tokyo, Japan). Post-ischemic liver tissues 
(wedge biopsies) were divided and either fixed in buffered formalin, 
paraffin-embedded and stained with hematoxylin and eosin for 
histological analysis, or frozen for adenine nucleotide (AN) and 
purine catabolite (PC) measurement. Results are presented as the 
mean:!: the standard error of the mean. Statistical analysis of the 
results was performed using the Log Rank test (for survival), and 
the Mann-Whitney U test (all others). A P-value less than .05 was 
considered significant. 
RESULTS 
Except for Group AI. the lazaroid infusion was well 
tolerated. Infusion of lazaroid A 1 (high dose) was associ-
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ated with arrhythmia and hypotension. Two-week animal 
survival in the control group (30%) was significantly worse 
than the treated groups (all but one treated animal survival 
the two-week follow-up). Lazarojd F or A treatment signif-
icantly improve liver function. The AST and AL T of control 
livers 12 hours after reperfusion were 1152 :t 1014 UIL and 
13563 :t 1379 UIL. respectively, while the highest AST and 
AL T of Group F and A livers were less than 5000 UIL. A 
postreperfusion increase of ir ET -1 levels in control animals 
was significantly suppressed in Group A2. Plasma MDA 
levels were significantly lower in the treated groups than in 
the control group. Hepatic tissue blood flow after reperfu-
sion was significantly better in the treated groups (>40% of 
preischemia) than in the controls (26.8 :t 1.7% of preisch-
emia). Compared with control, lazaroid treatment, espe-
cially Group A2. allowed less degradation of AN, less 
accumulation of Pc. and prompt restoration of AN after 
reperfusion. While the histology of post-reperfusion control 
livers showed marked abnormalities, lazaroid treated livers, 
particularly Group A2, were well preserved with only minor 
neutrophil infiltration. 
DISCUSSION 
Lazaroid treatment significantly ameliorated ischemia and 
reperfusion injury to the canine liver. Lazaroid treatment 
improved animal survival, improved liver function, sup-
pressed endothelin activity. decreased lipid peroxidation, 
accentuated hepatic tissue blood flow. and decreased ade-
nine nucleotide catabolism. 
As suggested in other studies. there appears to be a 
difference in the effectiveness of the different lazaroid 
compounds.4 Lazaroid A. at the lower (5 mg/kg) dose, was 
more effective in protecting the liver from ischemia and 
reperfusion injury than Lazaroid F or G. While all three 
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lazaroid compounds are potent anti-oxidants. U74500A 
is 2 to to times more effective in inhibiting iron-depen-
dent lipid peroxidation than U74006F," Conversely. 
U74006F and U74389G are more effective in scavenging 
lipid peroxyl radicals. like alpha-tocophenol. than 
U74500A.1.0 Thus, the increased potency of Lazaroid A 
in our model may suggest that early inhibition of lipid 
peroxidation by iron-chelation is more beneficial than 
scavenging lipid peroxyl radicals. 
The early resumption of energy metabolism, hepatic 
tissue blood flow, and suppressed endothelin-! production 
associated with lazaroid treatment in this study suggests 
that lazaroids protect not only the parenchymal hepato-
cytes, but the sinusoidal endothelial cells as well. Indeed. 
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histological architecture in the lazaroid treated groups. 
especially in Group A2. were well preserved. 
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